Comprehensive performance evaluation of ligand-binding assay-LC-MS/MS method for co-dosed monoclonal anti-SARS-CoV-2 antibodies (AZD7442).

导出 LinkOut

翻译打印收藏纠错

作者： Yue,Huang ^[1] ; Michael Shane,Woolf ^[2] ; Chun-Chi,Wang ^[3] ; Sami M,Naser ^[2] ; Aaron M,Wheeler ^[2] ; William R,Mylott ^[2] ; Eric,Ma ^[2] ; Anton I,Rosenbaum ^[1]

作者单位： Integrated Bioanalysis, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, South San Francisco, CA 94080, USA. ^[1] Chromatographic Services - Research & Development, Biologics by LC-MS/MS, PPD Laboratory Services (a part of Thermo Fisher Scientific), Richmond, VA 23229, USA. ^[2] Integrated Bioanalysis, Clinical Pharmacology & Safety Sciences, R&D, AstraZeneca, Gaithersburg, MD 20878, USA. ^[3]

关键词 SARS-CoV-2 hybrid IA–LC–MS/MS hybrid LBA–LC–MS/MS incurred sample reanalysis monoclonal antibody pharmacokinetics tixagevimab and cilgavimab validation

主题词人类(Humans);色谱法, 液相(Chromatography, Liquid);配体(Ligands);串联质谱法(Tandem Mass Spectrometry);抗体, 单克隆(Antibodies, Monoclonal);复方合剂(Drug Combinations);抗体, 中和(Antibodies, Neutralizing)

DOI 10.4155/bio-2023-0225

PMID 38385904

发布时间 2024-03-26

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交